Dose-dense chemotherapy for metastatic breast cancer
Author Information
Author(s): Lalisang R I, Voest E E, Wils J A, Nortier J W, Erdkamp F L, Hillen H F, Wals J, Schouten H C, Blijham G H
Primary Institution: Maastricht University Hospital
Hypothesis
Can the interval between chemotherapy cycles be safely reduced to increase dose intensity in patients with metastatic breast cancer?
Conclusion
The study found that epirubicin and paclitaxel can be safely administered every 10 days with G-CSF support, allowing for increased dose intensity.
Supporting Evidence
- The treatment regimen included epirubicin and paclitaxel with G-CSF support.
- Patients were treated in cohorts with intervals starting at 14 days and reduced to 10 days.
- No cumulative myelosuppression was observed over at least three consecutive cycles.
Takeaway
Doctors tested giving cancer medicine more often to help patients get stronger doses without making them too sick.
Methodology
A multicentre phase I/II study treating patients with epirubicin and paclitaxel at decreasing intervals.
Limitations
An 8-day interval was not feasible due to incomplete neutrophil recovery.
Participant Demographics
Patients with advanced breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website